55. The Chairman of the ad hoc Working Group, Dr J. Owusu (Australia), introduced the report and recommendations of the Group.
56. Australia, Brazil, Malaysia and Switzerland had recommended fluazuron to be included in the priority list and the European Community recommended cyfluthrin, cyhalothrin, danofloxacin, deltamethrin, florfenicol, griseofulvin, marbofloxacin, metrifonate, permethrin, phoxim, and sarafloxacin. Commitments were made by manufacturers for the provision of relevant data on cyfluthrin, danofloxacin and fluazuron in time for evaluation by the Forty-eighth meeting of JECFA in 1997, while the data for metrifonate would be available for evaluation at the Fiftieth meeting in 1998.
57. The Committee agreed to add cyfluthrin, danofloxacin, fluazuron and metrifonate to the priority list. It noted that cyfluthrin had already been evaluated by JMPR so its review would require close cooperation between JECFA and JMPR.
58. It was confirmed that data on apramycin would not be available in the near future and this substance was removed from the priority list. Nicarbazin was retained on the priority list pending the availability of data.
59. The provisional agendas for the Forty-eighth (February 1997) and Fiftieth (February 1998) meetings of JECFA are listed in Appendix VI. The agendas include substances that require re-evaluation for a number of reasons. Fluazuron, cyfluthrin and danofloxacin were added to the agenda of the Forty-eighth meeting of JECFA, and metrifonate was added to the agenda of the Fiftieth meeting of JECFA.
60. It was emphasized that following the recent GATT/WTO agreements, Codex standards had become important in resolving trading disputes. It was important that nominations continued to come forward and that these conformed with the criteria for inclusion on the priority list.
61. The Committee thanked the Working Group, its Chairman and the rapporteur for its work and agreed to set up the ad hoc Working Group at its next session under Dr. J. Owusu (Australia).
